EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Assessment of Outcome in 198 Patients With Mucinous Appendiceal Adenocarcinoma and Peritoneal Metastases Over 25 Years

Paul H Sugarbaker iD, David Chang

Journal of Surgical Oncology · 2026

DOI: 10.1002/jso.70283 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Surgical Oncology, 2026. Verfasst von Paul H Sugarbaker und 1 weiteren Autor:innen. Beteiligte Einrichtung: Washington Cancer Institute, Program in Peritoneal Surface Malignancy, Washington DC, USA. Hauptthemen laut MEDLINE: Appendiceal Neoplasms, Peritoneal Neoplasms, Adenocarcinoma, Mucinous. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Foundation for Applied Research in Gastrointestinal Oncology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A prognostic assessment of mucinous appendiceal adenocarcinoma (MACA) patients with peritoneal metastases in the absence of lymph node metastases needs to be precisely defined. All patients were treated by a complete cytoreductive surgery (CRS) and perioperative chemotherapy. Preoperative clinical features including tumor markers were recorded within 1 week prior to CRS. Data regarding perioperative intraperitoneal chemotherapy, histologic features and reoperative surgery were gathered after CRS. Impact on overall survival of these factors was analyzed by univariant and multivariant analysis. One hundred and ninety‐eight patients with mucinous appendiceal adenocarcinoma causing pseudomyxoma peritonei were available for study. They had a median survival of 11 years. Hyperthermic intraperitoneal chemotherapy (HIPEC) with a median survival of 12.0 years was superior to early postoperative intraperitoneal chemotherapy (EPIC) with a median survival of 4.0 years (HR 2.09, p = 0.002). By histopathology, the intermediate type (MACA‐Int) was associated with the longest survival and poorly differentiated (MACA‐3) the poorest survival. Peritoneal cancer index and tumor marker elevations had no impact on survival. Clinical features and preoperative tumor markers had little or no prognostic value in selection of MACA patients for CRS. Intermediate histologic subtype and use of HIPEC indicated a favorable outcome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Appendiceal NeoplasmsPeritoneal NeoplasmsAdenocarcinoma, MucinousHumansFemaleCytoreduction Surgical ProceduresHyperthermic Intraperitoneal ChemotherapyMiddle AgedMalePrognosisAdultSurvival RateAgedCombined Modality TherapyPseudomyxoma PeritoneiHyperthermia, InducedBiomarkers, Tumor

Stichwörter der Autor:innen

CA125CA19‐9EPICHIPECPseudomyxoma peritoneicytoreductive surgeryhyperthermiatumor markers CEA

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Washington Cancer Institute, Program in Peritoneal Surface Malignancy, Washington DC, USA.
  • Westat, Rockville, Maryland, USA.

ORCID-Profile: Paul H Sugarbaker

Förderung

  • Foundation for Applied Research in Gastrointestinal Oncology

Zitieren

APA

Sugarbaker, P. H., & Chang, D. (2026). Assessment of Outcome in 198 Patients With Mucinous Appendiceal Adenocarcinoma and Peritoneal Metastases Over 25 Years. Journal of Surgical Oncology. https://doi.org/10.1002/jso.70283

Vancouver

Sugarbaker PH, Chang D. Assessment of Outcome in 198 Patients With Mucinous Appendiceal Adenocarcinoma and Peritoneal Metastases Over 25 Years. Journal of Surgical Oncology. 2026. doi:10.1002/jso.70283

BibTeX
@article{Sugarbaker2026,
  author = {Sugarbaker, Paul H and Chang, David},
  title = {Assessment of Outcome in 198 Patients With Mucinous Appendiceal Adenocarcinoma and Peritoneal Metastases Over 25 Years},
  journal = {Journal of Surgical Oncology},
  year = {2026},
  doi = {10.1002/jso.70283}
}
Kostenlos starten →